October 26, 2020
Podcast
A glimpse into FDA advisor perspective just weeks before EUAs are anticipated to be sent.
October 25, 2020
Video
The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.
October 23, 2020
New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.
New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.
Article
The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.
October 21, 2020
New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.
A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.
October 20, 2020
October 16, 2020
Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.
October 13, 2020
